Twitter LinkedIn
    Wednesday, March 29
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Biotechnology»Private equity and biotechnology: Michael Johnson talks about the role investors play in the development of the biotech industry
    Biotechnology

    Private equity and biotechnology: Michael Johnson talks about the role investors play in the development of the biotech industry

    January 9, 2021Updated:January 9, 20213 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Michael Johnson, group head of institutional services at fund administrator Crestbridge, talks to Funds Europe about the role investors play in the development of the biotech industry.  

    What due diligence must private equity funds carry out when investing in biotechnology?

    With a high degree of interest in biotechnology even before the pandemic hit, private funds have been going in with their eyes wide open. Funds will seek out a product roadmap, check the science behind the potential product, look at preclinical pharmacology and toxicology reviews, investigate chemical manufacturing and supply chains and want to identify what intellectual property rights exist or are likely to in the future.

    Can private capital investors play a role in ensuring biotech isn’t used in nefarious ways?

    Certainly, especially as there is a heightened awareness around ESG [environmental, social, and governance] principles and impact investing amongst privates, their investors and amongst founders themselves. Many a pitch from a GP to an LP or a founder to a GP will have been rejected for not paying enough attention to ESG or impact principles. Founders often do have ESG or impact values at the core of their business philosophy, and will also be looking for backers who reflect or respect these values.

    What could one-off cures mean for investors seeking sustained cashflow?

    This is difficult to predict and we don’t yet know whether a possible Covid vaccine, for example, will be a one-off or require everyone to have vaccinations each and every year. However, in this sector very often a company that is able to pioneer a first is able to come out with a second, more profitable product. The first product may not even generate that much of a return but will have succeeded jumping a research or regulatory hurdle of some kind, that enables the firm to bring a second, related product to market much more easily and become more profitable.

    What potential do you think biotechnology has for revolutionising healthcare further and, subsequently, how investors approach the market?

    I wouldn’t want to make any predictions on the future nature of an industry, but there are many ongoing biotechnology projects specifically looking for the next idea that will revolutionise healthcare, well before Covid hit. For now, there’s certainly a feeling in the private [markets] industry that biotech will never be the same again: never before in human history has a vaccine been this close to being developed this quickly, and that takes a huge amount of resourcefulness and agility.

    Source: Funds Europe

     

     

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Biotechnology Crestbridge Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    KKR looking to sell Canadian gas producer Westbrick for $1.13B

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Comments are closed.

    Other Articles

    TPG takes majority stake in Santa Clara cybersecurity company and brings in a new CEO

    January 29, 2021

    Investment in private equity to reach USD1.2tn by 2025

    March 2, 2022

    GPD Companies, Inc completes acquisition of Distrupol

    April 5, 2021

    BlackRock Cuts Fees on World’s Biggest Bond ETF and Several More

    April 1, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?